NASDAQ:DYN Dyne Therapeutics (DYN) Stock Price, News & Analysis $17.04 -1.37 (-7.44%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$17.80 +0.76 (+4.43%) As of 06/5/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Dyne Therapeutics Stock (NASDAQ:DYN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Dyne Therapeutics alerts:Sign Up Key Stats Today's Range$16.63▼$18.6050-Day Range$15.92▼$20.4152-Week Range$8.06▼$25.00Volume1.88 million shsAverage Volume1.36 million shsMarket Capitalization$2.82 billionP/E RatioN/ADividend YieldN/APrice Target$35.00Consensus RatingModerate Buy Company Overview Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity. Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells. This strategy aims to address the challenges of systemic delivery and off‐target effects that have limited prior antisense and gene therapy efforts in neuromuscular disorders. By optimizing both the ligand and the cargo, Dyne seeks to achieve sustained target engagement in affected tissues while minimizing exposure elsewhere. Headquartered in Cambridge, Massachusetts, Dyne Therapeutics operates research and development facilities in the United States and collaborates with partners across Europe and Asia to support global clinical development. The company completed its initial public offering on the Nasdaq market in early 2021, enabling the expansion of its pipeline and investment in manufacturing capabilities for future late‐stage programs. Dyne’s leadership team brings together executives with extensive experience in biotechnology, pharmaceutical development and clinical operations. The company is governed by a board of directors and scientific advisory members who have led successful drug development programs across multiple therapeutic areas. Dyne continues to engage with patient communities, regulatory agencies and academic institutions to advance its mission of delivering next‐generation therapies for people living with devastating neuromuscular diseases.AI Generated. May Contain Errors. Read More Dyne Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreDYN MarketRank™: Dyne Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 337th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingDyne Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 3 strong buy ratings, 11 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialDyne Therapeutics has a consensus price target of $35.00, representing about 105.4% upside from its current price of $17.04.Amount of Analyst CoverageDyne Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Dyne Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Dyne Therapeutics are expected to grow in the coming year, from ($3.00) to ($2.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dyne Therapeutics is -5.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dyne Therapeutics is -5.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDyne Therapeutics has a P/B Ratio of 2.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Dyne Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.78% of the float of Dyne Therapeutics has been sold short.Short Interest Ratio / Days to CoverDyne Therapeutics has a short interest ratio ("days to cover") of 16.76, which indicates bearish sentiment.Change versus previous monthShort interest in Dyne Therapeutics has recently increased by 1.20%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDyne Therapeutics does not currently pay a dividend.Dividend GrowthDyne Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.95 News SentimentDyne Therapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Dyne Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 5 people have searched for DYN on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows2 people have added Dyne Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Dyne Therapeutics insiders have sold 17,636.32% more of their company's stock than they have bought. Specifically, they have bought $168,100.00 in company stock and sold $29,814,746.00 in company stock.Percentage Held by Insiders9.46% of the stock of Dyne Therapeutics is held by insiders.Percentage Held by Institutions96.68% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dyne Therapeutics' insider trading history. Receive DYN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DYN Stock News HeadlinesAnalysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Dyne Therapeutics (DYN) and Argenx Se (ARGX)June 5 at 6:50 PM | theglobeandmail.comDyne Therapeutics (DYN) Reaches Key Regulatory MilestoneJune 5 at 6:50 PM | finance.yahoo.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day. | Brownstone Research (Ad)A Look At Dyne Therapeutics (DYN) Valuation After Key ACHIEVE Trial Enrollment MilestoneJune 4 at 12:03 AM | nz.finance.yahoo.comBrian Posner Purchases 2,000 Shares of Dyne Therapeutics (NASDAQ:DYN) StockMay 29, 2026 | insidertrades.comInsider Buying: Dyne Therapeutics (NASDAQ:DYN) Director Acquires 2,500 Shares of StockMay 23, 2026 | insidertrades.comDyne Therapeutics (NASDAQ:DYN) CFO Sells $26,585.28 in StockMay 15, 2026 | insidertrades.comDyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 11,600 SharesMay 7, 2026 | insidertrades.comSee More Headlines DYN Stock Analysis - Frequently Asked Questions How have DYN shares performed this year? Dyne Therapeutics' stock was trading at $19.56 at the beginning of 2026. Since then, DYN stock has decreased by 12.9% and is now trading at $17.04. How were Dyne Therapeutics' earnings last quarter? Dyne Therapeutics, Inc. (NASDAQ:DYN) released its earnings results on Monday, May, 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.77) by $0.04. When did Dyne Therapeutics IPO? Dyne Therapeutics (DYN) raised $208 million in an IPO on Thursday, September 17th 2020. The company issued 12,251,578 shares at $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel acted as the underwriters for the IPO. Who are Dyne Therapeutics' major shareholders? Top institutional investors of Dyne Therapeutics include Janus Henderson Group PLC (8.26%), Perceptive Advisors LLC (2.82%), Orbimed Advisors LLC (1.77%) and Siren L.L.C. (1.35%). Insiders that own company stock include Venture Fund Xi LP Atlas, Joshua T Brumm, John Cox, Oxana Beskrovnaya, Douglas Kerr, Johanna Friedl-Naderer, Wildon Farwell, Jonathan Mcneill, Susanna Gatti High, Erick Lucera, Richard William Scalzo, Dirk Kersten, Brian S Posner, Jason P Rhodes and Carlo Incerti. View institutional ownership trends. How do I buy shares of Dyne Therapeutics? Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dyne Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dyne Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings5/11/2026Today6/05/2026Goldman Sachs 47th Annual Global Healthcare Conference 20266/09/2026Next Earnings (Estimated)7/27/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 DYN's financial health is in the Green zone, according to TradeSmith. DYN has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DYN Previous SymbolNYSE:DYN CIK1818794 Webwww.dyne-tx.com Phone781-786-8230Fax781-786-8866Employees100Year Founded2018Price Target and Rating Average Price Target for Dyne Therapeutics$35.00 High Price Target$50.00 Low Price Target$16.00 Potential Upside/Downside+105.4%Consensus RatingModerate Buy Rating Score (0-4)2.94 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($3.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$446.21 million Net MarginsN/A Pretax MarginN/A Return on Equity-58.28% Return on Assets-46.77% Debt Debt-to-Equity Ratio0.17 Current Ratio19.92 Quick Ratio19.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.81 per share Price / Book2.50Miscellaneous Outstanding Shares165,310,000Free Float149,675,000Market Cap$2.82 billion OptionableOptionable Beta1.09 Social Links The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:DYN) was last updated on 6/6/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredHow to get into the SpaceX IPO before June 12Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...Brownstone Research | SponsoredTesla. SolarCity. Twitter. This $4 stock is next.Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredShe called ASTS before it ran 133%. Here's the system behind it.Danielle Shay called AST SpaceMobile on Fox Business before it ran 133% - and found NBIS at $54 before it gapp...Simpler Trading | SponsoredWhy is this free?Simple Options Trading For Beginners normally sells for $29.97 - but right now Bill Poulos has opened a free w...Profits Run | SponsoredYou own these two timebombs — and can’t sell themTwo blue-chip stocks with a combined $100 billion market cap are sitting inside VOO, SPY, FXAIX, and virtually...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
